Mizuho Securities Keeps a Buy Rating on Concert Pharma (CNCE)


Mizuho Securities analyst Difei Yang maintained a Buy rating on Concert Pharma (CNCE) today and set a price target of $26. The company’s shares closed yesterday at $15.19.

Yang noted:

“We continue to see upside in CNCE shares, and believe limited value is currently assigned to CNCE’s multiple assets and drug development expertise.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.1% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Currently, the analyst consensus on Concert Pharma is a Moderate Buy with an average price target of $26, representing a 71.2% upside. In a report issued on February 14, JMP Securities also reiterated a Buy rating on the stock with a $26 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.15 and a one-year low of $10.80. Currently, Concert Pharma has an average volume of 143.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts